Wird geladen...
Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) remains resistant to chemotherapy and immunotherapy individually because of its desmoplastic stroma and immunosuppressive tumor microenvironment. Synergizing cytotoxic T‐lymphocyte–associated antigen 4 (CTLA‐4) immune checkpoint blockade with chemo...
Gespeichert in:
| Veröffentlicht in: | Oncologist |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
John Wiley & Sons, Inc.
2019
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7216436/ https://ncbi.nlm.nih.gov/pubmed/31740568 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0473 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|